203 related articles for article (PubMed ID: 24815078)
1. Does the presence of von Willebrand factor in FVIII-deficient plasma influences the measurement of FVIII inhibitor titres in haemophilia A patients?
Pouplard C; Desconclois C; Sobas F; Aillaud MF; Ternisien C; Caron C
Int J Lab Hematol; 2015 Feb; 37(1):125-32. PubMed ID: 24815078
[TBL] [Abstract][Full Text] [Related]
2. Native plasma-derived FVIII/VWF complex has lower sensitivity to FVIII inhibitors than the combination of isolated FVIII and VWF proteins. Impact on Bethesda assay titration of FVIII inhibitors.
Bravo MI; Da Rocha-Souto B; Grancha S; Jorquera JI
Haemophilia; 2014 Nov; 20(6):905-11. PubMed ID: 25156825
[TBL] [Abstract][Full Text] [Related]
3. Validation of 4% albumin as a diluent in the Bethesda Assay for FVIII inhibitors.
Kershaw GW; Chen LS; Jayakodi D; Dunkley SM
Thromb Res; 2013; 132(6):735-41. PubMed ID: 24119613
[TBL] [Abstract][Full Text] [Related]
4. The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitors.
Verbruggen B; Giles A; Samis J; Verbeek K; Mensink E; Novákovà I
Thromb Haemost; 2001 Dec; 86(6):1435-9. PubMed ID: 11776311
[TBL] [Abstract][Full Text] [Related]
5. Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis.
Veyradier A; Caron C; Ternisien C; Wolf M; Trossaert M; Fressinaud E; Goudemand J
Haemophilia; 2011 Nov; 17(6):944-51. PubMed ID: 21371195
[TBL] [Abstract][Full Text] [Related]
6. Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation.
Salvagno GL; Astermark J; Ekman M; Franchini M; Guidi GC; Lippi G; Poli G; Berntorp E
Haemophilia; 2007 Jan; 13(1):51-6. PubMed ID: 17212725
[TBL] [Abstract][Full Text] [Related]
7. Haemophilia A and von Willebrand's disease.
Goodeve AC; Rosén S; Verbruggen B
Haemophilia; 2010 Jul; 16 Suppl 5():79-84. PubMed ID: 20590861
[TBL] [Abstract][Full Text] [Related]
8. VWF/FVIII complex and the management of patient with inhibitors: from laboratory to clinical practice.
Berntorp E
Haemophilia; 2007 Dec; 13 Suppl 5():69-72. PubMed ID: 18078401
[TBL] [Abstract][Full Text] [Related]
9. [Modified Bethesda, modified Nijmegen and blank assays for coagulation factor VIII inhibitor detection and factors affecting the results].
Feng HM; Li Q; Xu WS; Chen DM; Zheng L
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Apr; 36(4):592-5. PubMed ID: 27113194
[TBL] [Abstract][Full Text] [Related]
10. Measurement of von Willebrand factor-FVIII binding activity in patients with suspected von Willebrand disease type 2N: application of an ELISA-based assay in a reference laboratory.
Zhukov O; Popov J; Ramos R; Vause C; Ruden S; Sferruzza A; Dlott J; Sahud M
Haemophilia; 2009 May; 15(3):788-96. PubMed ID: 19298374
[TBL] [Abstract][Full Text] [Related]
11. DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor.
Casonato A; Dannhauser D; Pontara E; Bertomoro A; Orazi B; Santarossa L; Zerbinati P; Girolami A
Blood Coagul Fibrinolysis; 1996 Jul; 7(5):549-53. PubMed ID: 8874865
[TBL] [Abstract][Full Text] [Related]
12. Improvements in factor VIII inhibitor detection: From Bethesda to Nijmegen.
Verbruggen B; van Heerde WL; Laros-van Gorkom BA
Semin Thromb Hemost; 2009 Nov; 35(8):752-9. PubMed ID: 20169511
[TBL] [Abstract][Full Text] [Related]
13. Standardisation of factor VIII and von Willebrand factor in plasma: calibration of the 4th International Standard (97/586).
Hubbard AR; Rigsby P; Barrowcliffe TW
Thromb Haemost; 2001 Apr; 85(4):634-8. PubMed ID: 11341497
[TBL] [Abstract][Full Text] [Related]
14. In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates.
Tagariello G; Zanotto D; Radossi P; Sartori R; Belvini D; Salviato R
Am J Hematol; 2007 Jun; 82(6):460-2. PubMed ID: 17211843
[TBL] [Abstract][Full Text] [Related]
15. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.
Mannucci PM; Shi Q; Bonanad S; Klamroth R
Haemophilia; 2014 Sep; 20 Suppl 6():2-16. PubMed ID: 24975700
[TBL] [Abstract][Full Text] [Related]
16. Comparative measurement of FVIII inhibitors in hemophilia A patients using ELISA and the Bethesda assay.
Kim SY; Kang SY; Lee WI
Korean J Lab Med; 2010 Jun; 30(3):260-3. PubMed ID: 20603586
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of modified Bethesda assay and Nijmegen assay in detecting FVII inhibitor in patients with hemophilia A].
Fan LK; Wang ZW; Hua BL; Su W; Wang SJ; Zhao YQ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):551-4. PubMed ID: 19968068
[TBL] [Abstract][Full Text] [Related]
18. The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies.
Shi Q; Schroeder JA; Kuether EL; Montgomery RR
J Thromb Haemost; 2015 Jul; 13(7):1301-9. PubMed ID: 25955153
[TBL] [Abstract][Full Text] [Related]
19. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model.
Behrmann M; Pasi J; Saint-Remy JM; Kotitschke R; Kloft M
Thromb Haemost; 2002 Aug; 88(2):221-9. PubMed ID: 12195693
[TBL] [Abstract][Full Text] [Related]
20. One-stage vs. chromogenic assays in haemophilia A.
Potgieter JJ; Damgaard M; Hillarp A
Eur J Haematol; 2015 Feb; 94 Suppl 77():38-44. PubMed ID: 25560793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
